Stay updated on Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.

Latest updates to the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision from v3.3.3 to v3.3.4 appears as a UI/version label update on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedAdded a new Locations section and entry for Beijing Municipality; the old Beijing Municipality Locations label was removed and the page now shows Revision: v3.3.3.SummaryDifference0.3%

- Check53 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2 in the page footer.SummaryDifference0.1%

- Check60 days agoChange DetectedRevision: v3.3.1 added and v3.2.0 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check67 days agoChange DetectedRemoval of the general government funding and operating-status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check81 days agoChange DetectedNo additions or deletions were detected between the two screenshots; the page content appears unchanged. The page continues to present study details for NCT04695470.SummaryDifference0.5%

Stay in the know with updates to Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.